Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Income from Continuing Operations data on file, last reported at 21281000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 12.28% year-over-year to 21281000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85726000.0 (down 7.28% YoY) and the FY2025 annual result came in at 45617000.0, down 26.07% from the prior year.
• Income from Continuing Operations eased to 21281000.0 in Q1 2026, from 19865000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 9247000.0 in Q2 2022 to a low of 58384000.0 in Q4 2022.
• A 5-year average of 18128625.0 and a median of 13430000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 563.0% — and 2023, when it surged 82.12%.
• Tracing ELDN's Income from Continuing Operations over 5 years: stood at 58384000.0 in 2022, then surged by 82.12% to 10437000.0 in 2023, then tumbled by 137.64% to 24802000.0 in 2024, then climbed by 19.91% to 19865000.0 in 2025, then dropped by 7.13% to 21281000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 21281000.0 (Q1 2026), 19865000.0 (Q3 2025), and 25626000.0 (Q2 2025), per Business Quant data.